Ina Tesseur
Overview
Explore the profile of Ina Tesseur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1731
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lukkarinen H, Vanninen A, Tesseur I, Pemberton D, Van Der Ark P, Kokkola T, et al.
J Alzheimers Dis
. 2022 Nov;
91(1):305-319.
PMID: 36404546
Background: Alzheimer's disease cerebrospinal fluid (CSF) biomarkers amyloid-β 1-42 (Aβ42), total tau (T-tau), and phosphorylated tau 181 (P-tau181) are widely used. However, concentration gradient of these biomarkers between intraventricular (V-CSF)...
2.
Lukkarinen H, Tesseur I, Pemberton D, Van Der Ark P, Timmers M, Slemmon R, et al.
J Alzheimers Dis
. 2021 Mar;
80(4):1629-1642.
PMID: 33720890
Background: Longitudinal changes in cerebrospinal fluid (CSF) biomarkers are seldom studied. Furthermore, data on biomarker gradient between lumbar (L-) and ventricular (V-) compartments seems to be discordant. Objective: To examine...
3.
Novak G, Streffer J, Timmers M, Henley D, Brashear H, Bogert J, et al.
Alzheimers Res Ther
. 2020 May;
12(1):58.
PMID: 32410694
Background: Atabecestat, a potent brain-penetrable inhibitor of BACE1 activity that reduces CSF amyloid beta (Aβ), was developed for oral treatment for Alzheimer's disease (AD). The long-term safety and effect of...
4.
Timmers M, Tesseur I, Bogert J, Zetterberg H, Blennow K, Borjesson-Hanson A, et al.
Neurobiol Aging
. 2019 May;
79:131-141.
PMID: 31055223
Amyloid β (Aβ) and tau are key hallmark features of Alzheimer's disease (AD) neuropathology. The interplay of Aβ and tau for cognitive impairment in early AD was examined with cross-sectional...
5.
Timmers M, Streffer J, Russu A, Tominaga Y, Shimizu H, Shiraishi A, et al.
Alzheimers Res Ther
. 2018 Aug;
10(1):85.
PMID: 30134967
Background: β-Secretase enzyme (BACE) inhibition has been proposed as a priority treatment mechanism for Alzheimer's disease (AD), but treatment initiation may need to be very early. We present proof of...
6.
Leinonen V, Rauramaa T, Johansson J, Bottelbergs A, Tesseur I, Van Der Ark P, et al.
J Alzheimers Dis
. 2018 Jun;
64(1):171-179.
PMID: 29865068
Background: Detection of pathological tau aggregates could facilitate clinical diagnosis of Alzheimer's disease (AD) and monitor drug effects in clinical trials. S-[18F]THK-5117 could be a potential tracer to detect pathological...
7.
Tesseur I, Nguyen A, Chang B, Li L, Woodling N, Wyss-Coray T, et al.
J Neurosci
. 2017 Apr;
37(17):4584-4592.
PMID: 28363982
Transforming growth factor-β (TGF-β) plays an important role in the development and maintenance of embryonic dopaminergic (DA) neurons in the midbrain. To study the function of TGF-β signaling in the...
8.
Espuny-Camacho I, Arranz A, Fiers M, Snellinx A, Ando K, Munck S, et al.
Neuron
. 2017 Feb;
93(5):1066-1081.e8.
PMID: 28238547
Human pluripotent stem cells (PSCs) provide a unique entry to study species-specific aspects of human disorders such as Alzheimer's disease (AD). However, in vitro culture of neurons deprives them of...
9.
Timmers M, Barao S, Van Broeck B, Tesseur I, Slemmon J, De Waepenaert K, et al.
J Alzheimers Dis
. 2017 Feb;
56(4):1437-1449.
PMID: 28157093
The β-site amyloid-β protein precursor (AβPP) cleaving enzyme-1 (BACE1) is the rate limiting enzyme in the generation of amyloid-β peptide (Aβ) from AβPP, one of the major pathways in Alzheimer's...
10.
Serneels L, Tesseur I, De Strooper B
Methods Mol Biol
. 2014 Jul;
1187:223-9.
PMID: 25053493
With the increasing appreciation of the role of Notch in development and disease, measuring its cleavage and signaling activity in cellular systems has become important. Here we describe a cell-based...